Blue dye cream takes on tough skin cancer in new trial
NCT ID NCT07311070
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a cream made from methylene blue, a common dye, on people with advanced basal cell carcinoma (a type of skin cancer) that cannot be treated with surgery or radiation. Twenty adults will apply the cream to their tumors every two days for one month. Researchers will measure whether the tumors shrink and how well the skin heals, with follow-up for six months. The goal is to find a safe, non-invasive option for patients who have run out of standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- methylene blue cream applied to the skin
- What this could lead to
- If it works, this could offer a non-invasive, low-cost treatment option for people with advanced skin cancer who cannot have surgery or radiation.
- What could go wrong
- This is a small early-phase trial with only 20 participants and no comparison group. The treatment may not shrink tumors or could cause skin irritation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BASAL CELL CARCINOMA (BCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mashhad University of Medical Sciences
Mashhad, Razavi Khorasan Province, Iran
More trials for these conditions
Other studies related to the condition(s) this trial covers.